Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Monoclonal Antibodies

Sanofi’s Amlitelimab Meets Phase 3 Goals in Eczema as Shares Fall on Tepid Efficacy

Analysts now view the OX40L antibody as a convenience-focused option with quarterly dosing rather than a direct rival to IL‑13/4 leaders.

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

One in Three Infants Received Preventive RSV Antibody in First Season, Study Finds

FDA Launches Roadmap to Phase Out Animal Testing in Drug Development

Pfizer's New Drug Shows Promise in Combatting Cancer-Related Weight Loss